A|B|C|D|E|F|G|H|I|J|K|L|M|N|O|P|Q|R|S|T|U|V|W|X|Y|Z|ALL

  检 索： 期刊名称 ISSN         高级检索

期刊名称：NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE ISSN： 1549-9634 出版频率： Bi-monthly 出版社： ELSEVIER, RADARWEG 29, AMSTERDAM, NETHERLANDS, 1043 NX   出版社网址： http://www.elsevier.com/wps/find/homepage.cws_home 期刊网址： http://www.elsevier.com/wps/find/journaldescription.cws_home/703416/description#description 影响因子： 6.458 主题范畴： NANOSCIENCE & NANOTECHNOLOGY;    MEDICINE, RESEARCH & EXPERIMENTAL 期刊简介(About the journal)    投稿须知(Instructions to Authors)    编辑部信息(Editorial Board)    About the journal Description Nanomedicine: Nanotechnology, Biology and Medicine (Nanomedicine) is a newly established, international, peer-reviewed journal published quarterly. Nanomedicine publishes basic, clinical, and engineering research in the innovative field of nanomedicine. Article categories include basic nanomedicine, diagnostic nanomedicine, experimental nanomedicine, clinical nanomedicine, and engineering nanomedicine, pharmacological nanomedicine. Nanomedicine provides the latest information in this rapidly developing field, both in research and clinical applications. The Journal publishes original clinical and investigative studies, state-of-the art papers, reports on new equipment and techniques, review articles, and more. Nanomedicine is the official publication of the American Academy of Nanomedicine (AANM). Instructions to Authors Guide for Authors Editor-in-Chief Chiming Wei, MD, PhD, FACC, FAHA Johns Hopkins University School of Medicine Executive Editor Tachung C. Yih, PhD, PE Oakland University, Michigan EDITORIAL OFFICE: Nanomedicine c/o Chiming Wei, MD, PhD Johns Hopkins University School of Medicine 600 Wolfe Street I Blalock 1206 Baltimore, MD 21205 Phone: 410-502-0622 E-mail: nanomedicine@gmail.com Aims and Scope of the Journal Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine) is an international, peer-reviewed journal. Each quarterly issue of Nanomedicine presents basic, clinical, and engineering research in the field of nanomedicine. Article categories include basic, diagnostic, experimental, clinical, engineering, pharmacologic, and toxicologic nanomedicine. In addition, regular features will address the commercialization of nanomedicine advances, ethics in nanomedicine, funding opportunities, and other topics of interest to researchers and clinicians. We invite authors to submit original manuscripts and review articles. Please send all manuscripts and related correspondence to the following address: Submission of Manuscripts Manuscripts must be submitted through the Nanomedicine online submission and review Web site ( http://ees.elsevier.com/nano ). Authors are requested to submit the text, tables, and artwork in electronic form (not as a PDF) to this address. All manuscripts submitted to the Journal must be original and must not have been previously published elsewhere or currently under consideration by another publication. In an accompanying letter, authors should state that the manuscript, or parts of it, have not been and will not be submitted elsewhere for publication. Submission items include a cover letter, suggested reviewers, the manuscript (including title page, abstract, manuscript text, references, and table/figure legends), tables, and figures. Revised manuscripts should also be accompanied by a unique file (separate from the covering letter) with responses to reviewers' comments. The preferred order of files is as follows: cover letter, suggested reviewers, response to reviews (revised manuscripts only), manuscript file(s), table(s), figure(s). Files should be labelled with appropriate and descriptive file names (e.g., SmithText.doc, Fig1.eps, Table3.doc). Upload text, tables and graphics as separate files. Do not import figures or tables into the text document and do not upload your text as a PDF. Complete instructions for electronic artwork submission can be found on the Author Gateway, accessible through the journal home page. Peer Review All manuscripts will be evaluated for completeness and adherence to submission guidelines and will then undergo a peer-review process. Provisional or final acceptance is based on originality, scientific accuracy, relevance, clarity, and topical balance of the Journal. Authors should suggest the names (with contact information) of three potential reviewers for the manuscript. Every attempt will be made to use at least one suggested reviewer. A request to submit a revised manuscript does not guarantee its acceptance, only that it will be reconsidered by the reviewers. Decisions will be communicated to the corresponding author by email. Conflict of Interest Authors are required to acknowledge all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. Each submission must also include a publishable statement disclosing any commercial associations, current and within the past five years, that might pose a potential, perceived or real conflict of interest. These include grants, patent licensing arrangements, consultancies, stock or other equity ownership, advisory board memberships, or payments for conducting or publicizing the study. This disclosure will be held in confidence during the peer review process and will not influence any editorial decision. If the paper is accepted for publication, such relationships may be disclosed in the Journal at the discretion of the Editor. When no competing interests are present, the publishable title page disclosure statement should say so. The editor asks each reviewer to disclose any competing interests or to recuse oneself if a competing interest might interfere with one's objectivity. National Institutes of Health Public Access Policy Certain repositories such as PubMed Central ("PMC") are authorized under special arrangement with Elsevier to process and post certain articles such as those funded by the National Institutes of Health under its Public Access policy (see elsevier.com for more detail on our policy). Articles accepted for publication in an Elsevier journal from authors who have indicated that the underlying research reported in their articles was supported by an NIH grant will be sent by Elsevier to PMC for public access posting 12 months after final publication. The version of the article provided by Elsevier will include peer-review comments incorporated by the author into the article. Because the NIH 'Public Access' policy is voluntary, authors may elect not to deposit such articles in PMC. If you wish to 'opt out' and not deposit to PMC, you may indicate this by sending an e-mail to mailto: NIHauthorrequest@elsevier.com. Requirements for studies involving live human or animal subjects: For studies that involved human or animal research, indicate approval by the institution's human or animal subject review committee in the Methods section of the manuscript. Include an additional statement of the humane care of the animals with animal studies and a statement of informed consent or exempt classification by the IRB with human studies. Content Types: BASIC NANOMEDICINE INVESTIGATIONS: Studies using nanotechnology to answer basic medical and biologic questions such as cell activity, DNA and RNA regulation, intracellular pathways, and nanosurgery. DIAGNOSTIC NANOMEDICINE INVESTIGATIONS: Studies using nanotechnology for diagnostic research and imaging development. EXPERIMENTAL NANOMEDICINE INVESTIGATIONS: Studies in laboratory animal experiments and in vitro experiments related to nanomedicine. CLINICAL NANOMEDICINE INVESTIGATIONS: Studies in clinical nanomedical science such as the approach of nanomedicine to prevent or treat different diseases. ENGINEERING NANOMEDICINE INVESTIGATIONS: Studies in development of engineering nanomedical technology in a medical specialty. PHARMACOLOGICAL NANOMEDICINE: Studies in drug delivery, pharmacologic mechanisms and particles. TOXICOLOGY NANOMEDICINE: Studies in side effects and toxicology. COMMERCIALIZATION OF NANOMEDICINE: Information regarding the commercialization of new products in the field. ETHICS IN NANOMEDICINE: Articles related to the ethical application of advances in nanomedicine. EDITORIAL COMMENTS: Invited articles or brief editorial comments that represent opinions of recognized leaders in nanomedicine research; length should not exceed 3000 words, and no more than 20 references should be cited. SCIENTIFIC REVIEWS: Review articles of selected important topics in nanomedicine research. Length should not exceed 10,000 words (including title page, abstracts, text, references, tables, and figure legends), and the article should have no more than 15 figures. No more than 150 references should be cited, which may be posted online only. BOOK REVIEWS: Reviews of selected books in nanomedicine, including books that present innovative concepts and books that describe state-of-the-art diagnostic or therapeutic methods or important advances; Authors should submit books for review to the Nanomedicine Editorial Office. TECHNICAL NOTES: Length of technical notes should not exceed 100 words (text 1200 words) 4 figures, and 10 references. CORRESPONDENCE: Letters to the Editor may not exceed 500 words with 10 references or fewer and one illustration or table. MEETING INFORMATION: Meeting information regarding upcoming nanomedicine conferences. Please contact Elsevier advertising department for rates (212-989-5800). Manuscript Preparation Full-length article manuscripts should not exceed 6000 words in total length (including title page, abstract, text, references, tables, and figure legends), or contain more than 10 tables and figures. Manuscripts must be typewritten, double-spaced and assembled in this order: title page, abstract, text, acknowledgments, references, figure legends, tables and figures, on one side of the page only. Leave 1-inch margins on all sides. All manuscripts must conform to "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" ( http://www.icmje.org ). PERMISSIONS: If any material has been published previously (figure, tables, etc), provide written permission from the copyright holder to use such material. Authors are responsible for obtaining permission and payment of any fees associated with reuse. TITLE PAGE: The title page should contain these elements: full title, all authors' names, academic degrees, and affiliations; first author's surname and short title (not to exceed 50 characters, including spaces); name and complete address for correspondence (include street name and address as well as PO box) and address for reprints if different from correspondence; fax and telephone number and e-mail address; conflict of interest statement if applicable; all sources of support for research. ABSTRACT: The abstract should not exceed 150 words and should summarize the content of the aricle. Insert 3 to 5 key words after the abstract. TEXT: The text should include the headings Background, Methods, Results, and Discussion. All pages must be numbered. Abbreviations must be parenthetically notated at first mention in the text. Each table and figure must be mentioned in the text. Reports of studies on humans and animals must indicate that each study was approved by an institutional review committee and the procedures followed were in accordance with institutional guidelines. Provide generic rather than trademarked names of drugs. ACKNOWLEDGMENTS: The acknowledgments section recognizes substantive contributions of individuals. The Editorial Office must receive written, signed consent from each person recognized in the acknowledgments to be mentioned in the article because acknowledgment can imply endorsement of data and conclusions. REFERENCES: Reference format should conform to that set forth in "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" ( http://www.icmje.org ) and journal abbreviations should conform to the style used in the Cumulated Index Medicus. Cite references, figures, and tables in numeric order according to the first mention in the text. Accuracy of reference data is the responsibility of the author. Verify all references against original sources. "In press" citations must have been accepted for publication and the name of the journal or book publisher must be included. The style of citation should be as follows: Journals: authors' last names and initials; title of article; journal name; date; volume number, and inclusive pages (list all authors when six or fewer; when seven or more, list six and add et al): 1. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:719-27. 2. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg 1999;117:855-72. Books: authors' last names and initials; chapter title, editor's name, book title, edition, city, publisher, date, and pages: 1. Mollnes TE. Analysis of in vivo complement activation: In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, editors. Weir's handbook of experimental immunology. Volume 78, 5th ed. Boston: Blackwell Science; 1997, p. 78.1-78.8. Unpublished data and personal communications should be cited only in the text, not as a numbered reference. Authors wishing to cite unpublished material must have a letter of permission from the originator of the communication to do so. This letter should be submitted with the manuscript. FIGURES: Figures must be of professional quality. When possible, please use or supply first-generation artwork. Figures are encouraged in electronic format with a printed proof on glossy or high-quality photographic printer paper. Figures may be black and white line art, graphs, halftones (photographs), or color. TIFF, EPS, or PDF formats are recommended for electronic artwork. Line art should have a minimum resolution of 1000 dpi, halftone art a minimum of 300 dpi, and combination art (line/tone) a minimum of 500 dpi. Produce images near to the desired size of the printed version. Illustrations should be saved at the recommended resolution setting and sized as closed to a column width (3 to 4 inches) as possible. Create figures in scale with each other to the extent possible. Avoid background gridlines and other formatting that do not convey information (eg, superfluous use of 3-dimensional formatting, background shadings). Use uniform lettering and sizing of all original artwork. As a general rule the lettering on the artwork should have a finished, printed size of 7 points. Smaller lettering will yield barely legible text. Recommended font choices include Arial, Helvetica, or Symbol. Labeling of multipart figures (eg, A, B, C...) should be done consistently, preferably using uppercase type (Arial, Helvetica or Universe, 11 or 12 points) in the lower-right corner of the figure. Avoid headings on the figure when possible. Additional information on preparation of electronic artwork can be found in the Artwork Instructions available at http://authors.elsevier.com/ . For best results, please follow these guidelines carefully. Publication of color illustrations in the print Journal will be charged to the author. TABLES: Table numbers should be Arabic, followed by a period and a brief title. Begin each table on a separate page. Use same size type as in text where possible. Supply a brief heading for each column. Do not use vertical lines between columns. Use horizontal lines above and below the column headings and at the bottom of the table only. Use extra space to delineate sections within the table. Abbreviations used in the table must be defined in a footnote to the table. Indicate footnotes in this order: *,? ? ? ? #, **, ††, ‡‡, §§, ¶¶, ##. OFFPRINTS: Offprint order forms will be sent to authors before articles are published. Reprints in quantity must be purchased from the Publisher. Editorial Board Editorial Board Editor-in-Chief: Chiming Wei, MD, PhD Johns Hopkins University School of Medicine Executive Editor: Tachung C. Yih, PhD, PE Oakland University, MI Editorial Board: Mauli C. Agrawal PhD San Antonio, TX Jaimie Anderson PhD Atlanta, GA Krishna Balakrishnan MD Rockville, MD Gang Bao PhD Atlanta, GA Raj Bawa PhD Ashburn, VA Earl J. Bergey PhD Buffalo, NY Robert G. Best PhD Columbia, SC Jeff W. M. Bulte PhD Baltimore, MD Han Cao PhD Philadelphia, PA James Castracane PhD Albany, NY Jung-Chih Chiao PhD Arlington, TX David F. Counts PhD Philadelphia, PA James Crowe MD Nashville, TN Melik C. Demirel PhD University Park, PA Sanjay Desai MD, PhD Rockville, MD Mrinal K. Dewanjee MSc, PhD Bethesda, MD Bogdan Dragnea PhD Bloomington, IN Michael Dustin PhD New York, NY William Dynan PhD Atlanta, GA Douglas C. Eaton PhD Atlanta, GA Mauro Ferrari PhD Columbus, OH Allison R. Ficht PhD College Station, TX Ted Flynn MPA Dulles, VA Robert A. Freitas Jr JD Pilot Hill, CA Tom B. Friedman PhD Rockville, MD Susan Gilbert PhD Pittsburgh, PA James K. Gimzewski PhD, Cphys Los Angeles, CA Robert I. Glazer PhD Washington, DC Steve Goldstein MD, PhD Chicago, IL Perenal Gouma PhD Stony Brook, NY Peixuan Guo PhD West Lafayette, IN Ram B. Gupta PhD Auburn, AL John M. Hallenbeck MD Bethesda, MD John G. Hartley PhD Albany, NY Michael J. Heller PhD San Diego, CA Lawrence Hofmann MD Baltimore, MD Gareth Hughes PhD Richardson, TX Erick Jakobsson PhD Urbana-Champaign, IL Valerian E. Kagan PhD Pittsburgh, PA Ernest S. Kawasaki PhD Bethesda, MD Ishrat M. Khan PhD Atlanta, GA George Khushf PhD Columbia, SC Jin-Woo Kim PhD Fayetteville, AR Katrin Kneipp PhD, DSc Boston, MA Jay R. Knutson PhD Bethesda, MD Dara L. Kraitchman PhD, VMD Baltimore, MD Richard D. Leapman PhD Bethesda, MD Kam Leong PhD Baltimore, MD Jun Li PhD Moffett Field, CA King C. Li MD Bethesda, MD Yuehe Lin PhD Richland, WA Stuart Lindsay PhD Tempe, AZ Robert Lu PhD Philadelphia, PA Yuri Lyubchenko PhD, DSc Omaha, NE Scott E. McNeil PhD, NCI Frederick, MD Carlo D. Montemagno PhD Los Angeles, CA Richard Mu PhD Nashville, TN Golam Newaz PhD Detroit, MI Hayat Onyuksel PhD Chicago, IL Aristides A. G. Requicha PhD Los Angeles, CA Peter Searson PhD Baltimore, MD Michael P. Sheetz PhD New York, NY Michael L. Simpson PhD Oak Ridge, TN Keshav K. Singh PhD Buffalo, NY Larry Sklar PhD Albuquerque, NM Lydia Sohn PhD Berkeley, CA Phang C. Tai PhD Atlanta, GA E. Clayton Teague PhD Arlington, VA Michael Teitell MD Los Angeles, CA Nitish Thakor PhD Baltimore, MD Z. Ryan Tian PhD Fayetteville, AZ Gregory Timp PhD, Urbana-Champaign, IL Donald Tomalia PhD Mt. Pleasant, MI Donna Wang PhD East Lansing, MI Jeff Wang PhD Baltimore, MD Kang Wang PhD Los Angeles, CA Kuan Wang PhD Bethesda, MD Zhong Lin Wang PhD Atlanta, GA Dennis Wirtz PhD Baltimore, MD Tamae Wong PhD Washington, DC Min Wu MD PhD Grand Forks, ND Ning Xi DSc East Lansing, MI Bai Xu PhD Albany, NY Judith C. Yang PhD Pittsburgh, PA Mingjun Zhang PhD Palo Alto, CA Weilie Zhou PhD New Orleans, LA International Editors: Ueli Aebi PhD Basel, Switzerland Chunli Bai PhD Beijing, China Katarina Edwards PhD Uppsala, Sweden Michael Horton PhD London, UK Stephan M. Huber PhD Tuebingen, Germany Kostas Kostarelos PhD London, UK Kohji Mitsubayashi PhD Tokyo, Japan Takeharu Nagai PhD Sapparo, Japan Boaqin Qiang PhD Beijing, China Raju V. Ramanujan PhD Singapore Uwe B. Sleytr PhD, Dipl Ing Vienna, Austria Peter Stockley PhD Leeds, UK Tsuneo Urisu PhD Okazaki, Japan Sishen Xi PhD Beijing, China